CYCLE Pharmaceuticals, The University of Cambridge and King’s College London Partner to Repurpose PARP Inhibitor Drugs for Vascular Disease

By |2021-05-17T18:52:31+01:00December 19th, 2016|News|

CYCLE Pharmaceuticals Nitisinone Tablets Approved by Health Canada for the Treatment of HT-1

By |2021-05-17T18:52:31+01:00November 8th, 2016|News|
Go to Top